Market Research

A robotic system is a type of automation that has multiple axes of motion and can be programmed to perform a function. Some of the benefits of automation include efficiency, saving workers from hazardous environments or repetitive tasks, reducing training overhead, eliminating human error, increasing repeatability and reproducibility, and in cleanrooms, removing the potential for human contamination.

[141 Pages Report] The overall pharmaceutical robotic systems market is expected to grow from USD 64.37 million in 2016 to USD 119.46 million by 2021, at a CAGR of 13.2% from 2016 to 2021.

Market Dynamics

• Benefits offered by robotic systems in pharmaceutical manufacturing
• Conferences and exhibitions to raise awareness of robotic systems in pharmaceutical manufacturing

Robotic systems provide various benefits to pharmaceutical manufacturing such as lesser space utilization, reduced production downtime, no labor turnover, enhanced health and safety, better waste management, increased production flexibility, improved production output and product quality, and lower operating costs. With the growing pharmaceutical industry and the various benefits offered by robotic automation, the adoption of robots is likely to increase in the coming years.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210985096  

On the basis of application, the global pharmaceutical robotic systems market is segmented into picking and packaging, inspection of pharmaceutical drugs, and laboratory applications. The picking and packaging segment accounted for the largest share of the global pharmaceutical robotic systems market.

The geographical regions mapped in the report are:

1. North America

2. Europe

3. Asia-Pacific

4. RoW

The pharmaceutical robotic systems market in APAC is expected to grow at the highest CAGR during the forecast period owing to factors such as the increase in domestic industrial robots companies, flourishing pharmaceutical industry, increasing number of conferences and exhibitions, investments and funding in the industrial robots industry, and Japan’s Robot Strategy.

Some key players mentioned in the research report are:

Key players considered in the analysis of the pharmaceutical robotic systems market are Kawasaki Heavy Industries Ltd. (Japan), FANUC Corporation (Japan), KUKA AG (Germany), Mitsubishi Electric Corporation (Japan), ABB Ltd. (Switzerland), Denso Corporation (Japan), Seiko Epson Corporation (Japan), Marchesini Group S.p.A (OTCPK:ITALY), Universal Robots A/S (Denmark), Yaskawa Electric Corporation (Japan), and Shibuya Corporation (Japan).

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=210985096  

The HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments. The software segment is expected to register the highest growth during the forecast period.

[166 Pages Report] MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (OTC:OTC:CAGR) of 10.3% during the forecast period

The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.

Market Dynamics

• Need for Cost Containment in Pharmaceutical R&D
• Government Funding and Venture Capital Investments Across Developed Markets
• Advancements in Informatics Solutions and Imaging Instruments

Download PDF Brochure@  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391

Need for cost containment in pharmaceutical R&D

According to the California Biomedical Research Association (CBRA), it takes an average of 12 years for a drug to travel from the research lab to the patient, including 1–6 years for toxicology studies alone. In addition, only five in 5,000, or 10%, of the drugs that begin preclinical testing ever make it to human testing. Out of these five, only one is approved for human usage.

HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies. As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies. Moreover, budgetary restrictions among academic institutes restrict the purchase of these instruments.

The geographical regions mapped in the report are:

North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors contributing to the large share of North America in the market.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=42710391

Some key players mentioned in the research report are:

GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.)

The key trends for increase in market, by public health organization are the growing expenditure on drugs and medical devices by public health organizations, steps by the government to build up strong analytical testing abilities, increasing number of drug approvals and clinical trials, and rising demand for specialized analytical testing services.

[68 Pages Report] The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 Million by 2021 from USD 202.8 Million in 2016, at a CAGR of around 10.5% during the forecast period.

The overall market, by public health organization is positively impacted by factors such as the growing expenditure on drugs and medical devices by public health organizations, government initiatives to strengthen analytical testing capabilities, increasing number of drug approvals & clinical trials, and rising demand for specialized analytical testing services.

Market Dynamics

• Growing Expenditure on Drugs and Medical Devices By Public Organizations
• Government Initiatives to Strengthen Analytical Testing Capabilities
• Increasing Number of Drug Approvals and Clinical Trials
• Rising Demand for Specialized Analytical Testing Services

On the basis of type of service, the spend assessment is segmented into eight segments, namely, bioanalytical testing, batch release testing, stability testing, raw material testing, physical characterization, method validation, microbial testing, and environmental monitoring.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65590498  

This growth can be attributed to factors such as the usage and development of a large number of macromolecules and Biosimilars for various therapeutic areas and the growing biopharmaceutical industry across the globe. The spending on batch release testing services is expected to account for the second largest share during the forecast period.

The geographical regions mapped in the report are:

Geographically, the market, by public health organization is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2015, North America commanded the largest share, followed by Europe, Asia-Pacific, and the RoW. The major share of this region can be attributed to the high expenditure on quality testing, strong regulatory scenario, increasing number of clinical trials, and the well-established federal testing laboratories in the region. Moreover, Asia-Pacific is expected to grow at the highest CAGR during the forecast period.

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=65590498  

Some key players mentioned in the research report are:

Food and Drug Administration (U.S.), European Medicines Agency (U.K.), Federal Institute for Drugs and Medical Devices (Germany), Agence française de sécurité sanitaire des produits de santé (France), Agenzia Italiana del Farmaco (OTCPK:OTCPK:ITALY), the Spanish Medicines and Health Products Agency (Spain), Central Drugs Standard Control Organization (India), China Food and Drug Administration, and Pharmaceuticals and Medical Devices Agency (Japan).

This study estimates the market size for 2016 and projects its demand till 2021. Primary and secondary research was used to for market estimation and forecast. Various secondary sources such as directories, industry journals, and databases have been used to identify and collect information useful for this extensive commercial study of the market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the market.

The global aesthetic lasers market is estimated to grow at a CAGR of 10.2% during the forecast period, to reach USD 1,132.7 Million by 2021.

Growing adoption of noninvasive procedures, changing lifestyles, rising incidence of skin damage, reduction in procedural costs, and rise in medical tourism devices are the major factors driving the growth of the aesthetic lasers market. However, the rising adoption of energy-based devices and low focus of market players on aesthetic/cosmetic devices are restraining the growth of this market.

Market Dynamics

• Growing Adoption of Non-Invasive Aesthetic Procedures
• Changing Lifestyle and Growing Disposable Income
• Technological Advancements
• Growing Medical Tourism

The aesthetic lasers market is segmented on the basis of type, application, end user, and region. On the basis of type, the market is segmented into standalone lasers and multiplatform lasers. Standalone lasers are further segmented into carbon dioxide (CO2) lasers, erbium YAG lasers, diode lasers, pulsed dye lasers, Nd:YAG lasers, alexandrite lasers, other standalone lasers (argon, ruby, krypton lasers, and erbium:glass lasers). Standalone lasers have advantages such as simplicity of functioning and ease of use which has significantly boosted their adoption and accounts for the highest market share of the aesthetic lasers market in 2016.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94673613 

Based on type, the aesthetic/cosmetic lasers type market is segmented into standalone lasers and multiplatform lasers. In this market, multiplatform lasers formed the fastest-growing segment as they provide scalable and upgradeable hybrid systems that can treat multiple indications. Factors such as multiplatform lasers provide clinicians the flexibility and versatility of several standalone systems in a single package, and provide combination therapy to synergistically treat a single indication or provide treatment addressing multiple elements of any indication is contributing to the high growth of this segment in the forecast period.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Rest of the World (RoW)

The market is segmented into four major regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Among these regional segments, North America is expected to account for the largest share of the global aesthetic lasers market. However, the Asia-pacific is expected to grow at the highest CAGR during the forecast period. The high growth in this regional segment can be attributed to factors changing lifestyles, rising incidences of skin damage, and increasing medical tourism in the region will drive the growth of this market..

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=94673613 

Dearth of training for vascular surgeons, high cost of varicose vein treatment procedures, and implementation of healthcare reforms in the U.S. are some of the key factors restraining the growth of market. In addition to this, challenges associated with inconsistent reimbursement scenario for varicose vein treatment procedures and sustainability of players in the highly competitive market also limits the growth of the market.

What the Market Looks Like?

The varicose vein treatment market is projected to reach to reach $289.7 million by 2021 from $207.9 million in 2016, growing at a CAGR of 6.9% from 2016 to 2021. This report covers the market across two major geographies, namely, North America and Europe.

Shift towards less-invasive treatment procedures, availability of advanced varicose vein treatment devices, and huge burden of varicose vein cases in North America and Europe is driving the growth of the market. Other growth factors include improving patient compliance & reliability, growing healthcare expenditure, and rapid growth in aging population.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=22524107

Objectives of the study are :

• To define, describe, and forecast the market in North America and Europe on the basis of mode of treatment, products, and regions
• To provide detailed information regarding major factors influencing the growth of the market in North America and Europe (drivers, restraints, opportunities, and industry-specific challenges)
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To strategically profile the key players and comprehensively analyze their market shares
• To estimate and forecast the market by mode and product in North America (U.S. and Canada) and Europe (Germany, U.K., France, Italy, Spain, and Rest of Europe)

This report broadly segments the Varicose Vein Treatment market into mode of treatment and products. On the basis of mode of treatment, the market is segmented into endovenous ablation, injection sclerotherapy, and surgical ligation/stripping. The endovenous ablation segment is expected to command the major share of the market, by mode of treatment, in 2016.

Read more about Varicose Vein Treatment Modes Market @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=22524107

According to the new market research report “Walking Assist Devices Market by Product Type (Gait Belts & Lift Vests, Canes, Crutches, Walker, Wheelchairs, Power Scooters), and Region (North America, Europe, Asia-Pacific and ROW) – Global Forecast ” published by MarketsandMarkets™

The global walking assist devices market is expected to reach $6.57 Billion by 2020, at a CAGR of 3.9% from 2015 to 2020.

The global market is expected to witness growth in the coming years, owing to factors such as the increase in the number of initiatives undertaken by governments of various countries to ensure availability of walking assist devices to a huge consumer base, rise in aging population, and increasing incidences of Debilitating Neurological Diseases & Injuries

The market is broadly segmented on the basis of product and geography. Based on product, the global market is classified into gaits belts and lift vests, canes, crutches, walkers, wheelchairs, and power scooters. The wheelchairs segment of the global market is the largest and also the fastest growing segment.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=24035174

Walking Assist Devices Market Stakeholders :

• Companies Manufacturing Walking Assist Devices
• Medical Device Distributors
• Healthcare Institutions (Hospitals, Medical Schools, and Governing Bodies)
• Health Insurance Providers
• Research and Consulting Firms
• Regulatory Authorities

The walking assist devices are generally used by the patients suffering from spinal cord injuries (SCI), hemiplegia and other types of paralysis, multiple sclerosis (MS), cerebral palsy (CP), amyotrophic lateral sclerosis (ALS), arthritis, and lower-limb amputations.

Request for sample pages @   https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=24035174

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific (APAC)4. Rest of the WorldGeographical Growth Analysis:

North America accounted for the largest share in the global walking assist devices market in 2014. The walking assist devices market in the North American region is mostly driven by factors, such as presence of supportive government policies, sophisticated healthcare infrastructure, and increasing geriatric population base.

The veterinary care market is expected to foresee positive trends throughout the forecast period. Substantial market growth can be attributed to the rising initiatives undertaken by the regulatory authorities. Government authorities collaborate with veterinarians and develop schemes that assure the availability of optimum inventory at fields for treating the farm animals.

Latin America animal health market size is projected to reach around USD 9 billion by 2025 from around USD 5.2 billion in 2018, at a CAGR of 7.3% during the forecast period.

This study involved the extensive use of both primary and secondary sources. The research process included a study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Recent Developments

• In February 2020, Zoetis acquired Ethos Diagnostic Science. This acquisition will not only expand company’s product portfolio but will also help the company to grow exponentially in the veterinary space.
• In November 2019, Zoetis acquired ZNLabs a reference laboratory company that is operational across the U.S. This has helped the company to enhance its offerings and improve its business performance
• In June 2020, Merck completed the acquisition of a Quantified Ag leading data analytics company that monitors cattle temperature and helps in the early detection of any disease. This acquisition will diversify Merck’s veterinary product offerings and will positively impact the company’s profitability.

The animal type segment of the veterinary care market is bifurcated further into dogs, cats, pigs, poultry, cattle, and horses. Livestock animals such as cattle and poultry are expected to experience higher medicalization rates during the forecast years. In emerging economies such as the Philippines and Vietnam, earlier, poultry health was neglected, and owners used to discard the chickens in bulk during a virus outbreak.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=78396315  

Based on the type of treatment, the veterinary care market is segmented into no medicalization, basic medicalization, and under veterinary care. The percentage of non-medicalized animals is going to experience a decline over the next few years. The major reason behind this sharp decrease in no medicalization in animals is rising awareness amongst the farm as well as the pet owners.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Africa5. Latin America

Latin America is one of the regions that has experienced significant growth in animal health space for the past few years. Countries such as Brazil and Argentina have shown potential demand for veterinary products and services. Several major players in the veterinary space have considered expansion Latin America due to the enormous growth opportunities it offers in the animal health industry.

Some key players mentioned in the research report are:

The leading players in the animal treatment market include Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Virbac SA (France), IDEXX Laboratories, Inc., Neogen Corporation (US), Heska Corporation (US) and others. These players undertake several strategic initiatives such as mergers, acquisitions, new product launches, and geographical expansions that helps them in sustaining market competition.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=78396315  

Major Growth Boosters :

Growth in this market is driven majorly by the growth of the biologics sector, increasing research & development expenditure, rising purity demands in end-use markets, and the growing development of large molecule biopharmaceuticals.

Expected Revenue Growth:

[138 Pages Report] The global solvent evaporation market size is projected to reach USD 694 million by 2024 from USD 487 million in 2019, at a CAGR of 7.3%.

What This Report Will Provide?

In this report, the global market for solvent evaporators was arrived at after the assessment of major product segments and their shares. For this purpose, the share of major product segments was determined through various insights gathered during primary and secondary research.

The research process involved the study of multiple factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=68290365

Recent Developments

• In June 2019, Yamato Scientific relocated its headquarters to Tokyo, Japan.
• In July 2019, Organomation Associates, Inc. partnered with BioChromato to provide a vacuum-assisted Smart Evaporator to customers in North America.
• In April 2018, Yamato Scientific opened its new R&D Center in Saitama Prefecture, Japan.
• In May 2017, Organomation Associates enhanced its MICROVAP product line with the addition of four new product offerings.

The research & academic institutes end-user segment is expected to grow at a high CAGR

The solvent evaporation market, by the end-user, includes pharmaceutical & biopharmaceutical industry, diagnostic laboratories, and research & academic institutes. The research & academic institutes segment is expected to grow at the highest CAGR during the forecast period due to factors such as the increasing drug development studies and the rising demand for continuous innovation and enhancement of existing products.

Request for sample pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=68290365

Regional Growth Analysis:

The North American market accounted for the largest share of the solvent evaporators industry in 2018. This is attributed to the increase in life sciences R&D, rising focus on improving the safety & quality of healthcare, growing efforts to increase the output of the healthcare industry, growth in the biosimilars & generics market, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.

Expected Revenue Growth:

[116 Pages Report] The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period.

Major Growth Drivers:

Growth in this market is driven by the rising global prevalence of hematologic cancer, growing awareness regarding personalized medicines, and increasing collaborations for developing new assays. On the other hand, Uncertain reimbursement scenario in different regions is expected to restrain the growth of this market during the forecast period.

Recent Developments:

1. In May 2018, Adaptive Biotechnologies (US) collaborated with Sanofi, SA. (US), to utilize Adaptive’s clonoSEQ Assay to measure MRD status in response to isatuximab2. In July 2018, Abbott Laboratories (US) received FDA approval for its Abbott RealTime IDH1 kit3. In May 2018, Invivoscribe, Inc. (US) partnered with the American University of Beirut Medical Center (AUBMC) (Lebanon) to create a new center of excellence facility in the Middle East

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877

“The services segment accounted for the largest share of the hemato oncology testing in 2018”

Based on product & services, the hemato oncology testing is segmented into services and assay kits. In 2018, the services segment accounted for the largest share of the hemato oncology testing. This is mainly due to the increasing prevalence & incidence of leukemia, non-Hodgkin lymphoma, and myeloma cancers. Apart from this, rising awareness regarding advanced treatment therapies such as personalized medicine is also driving the growth of this segment.

“Asia Pacific to register the highest growth rate during the forecast period (2019–2024)”

Based on region, the hemato oncology testing is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). While North America dominated the market in 2018, Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC market is driven mainly by the large patient population, and increasing focus of major players on expanding in this region will drive market growth.

Request for sample pages :   https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877

Key Market Players

Prominent players in the hemato oncology testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Major Growth Drivers:

Factors such as increasing R&D spending, growth in the biopharmaceutical industry, and increasing purity requirements in the end-user market are driving the growth of the market.

Expected Revenue Growth:

[106 Pages Report] The filter integrity test market is projected to reach USD 79 million by 2024 from USD 59 million in 2018, at a CAGR of 5.0% during the forecast period.

The filter integrity test market comprises several stakeholders such as raw material suppliers, manufacturers of filter integrity test, and regulatory organizations in the supply chain. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The primary interviewees from the demand side include key opinion leaders in research laboratories, academic institutes, and pharmaceutical & biotechnology companies.

Browse in-depth TOC on “Filter Integrity Test Market“

80 – Tables

27 – Figures

106 – Pages

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46873904

Pharmaceutical and biopharmaceutical companies are the largest and fastest-growing end users of the filter integrity test market.

Based on end user, the filter integrity test market is segmented into pharmaceutical and biopharmaceutical companies, CMOs, and other end users. In 2018, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market. This segment is also expected to witness the highest growth during the forecast period owing to the growing biopharmaceutical industry, significant growth in the biologics market, and stringent government guidelines for purity requirements in pharmaceutical and biotechnology manufacturing.

Regional Growth Analysis:

The market is divided into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest share of the market, followed by Europe. The increasing demand for biopharmaceuticals and implementation of drug safety guidelines by the FDA are the major factors driving the growth of the filter integrity test industry in North America.

Request for sample pages :  https://www.marketsandmarkets.com/requestsampleNew.asp?id=46873904

Key Market Players

The major players in the filter integrity test market are Merck KGaA (Germany), Danaher Corporation/Pall Corporation (US), Sartorius (Germany), Donaldson Company (US), Parker Hannifin Corporation (US), Meissner Filtration Product (US), MDI Filtration Technologies (US), Thermo Fisher Scientific (US), Eaton Corporation (Ireland), and SH-Surway (NASDAQ:CHINA).

According to the new market research report “ Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) – Forecast to 2023“, published by MarketsandMarkets™, global particle therapy market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%.

Exhaustive secondary research was done to collect information on the market and its different subsegments. The study involved four major activities to estimate the current market size for particle therapy. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Major Growth Drivers:

Growth in the particle therapy market is primarily driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.

Expected Revenue Growth:

The particle therapy market is projected to grow from an estimated USD 865 million in 2018 to USD 1,349 million by 2023, at a CAGR of 9.3% during the forecast period.

Synchrotrons are used to accelerate both protons and heavy ions such as carbon and hydrogen. The growth of the synchrotrons segment is attributed to factors such as the increasing number of research activities as well as the increasing investments in the development of synchrotron facilities.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137 

The large share of the proton therapy segment can be attributed to factors such as the high degree of precision, shorter treatment time, and reduced side-effects associated with proton therapy as compared to conventional photon therapies using X-rays. Other factors such as the increasing research activities in the field of radiation oncology using proton therapy systems, rising number of proton therapy centers, and longer equipment lifespan of proton therapy (30 years or more) in comparison to photon therapy (10 years) are expected to support the growth of this market in the coming years.

Asia Pacific is expected to hold a significant share in the particle therapy market during the forecast period

The Asia Pacific is one of the major revenue generating regions in the particle therapy market. China and Japan are the major countries responsible for the high growth of this regional market owing to factors such as the increasing per capita income, improving healthcare infrastructure, and supportive government activities in these emerging countries. Furthermore, the increasing geriatric population, growing incidence of cancer, and rising acceptance of particle therapy procedures and devices are also driving the growth of this regional market.

Request for sample pages :  https://www.marketsandmarkets.com/requestsampleNew.asp?id=12809137 

According to the new market research report “ Transfer Membrane Market According to the new market research report “ Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies)”, published by MarketsandMarkets™,transfer membrane market is projected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period.

Expected Revenue Growth:

The global transfer membrane market is expected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period.

Major Growth Drivers:

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.

Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of market.

The report analyzes the global market by type, transfer method, application, end user, and region.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36975865 

This report covers the market data across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global transfer membrane market in 2018, followed by Europe. The large share in the North American region is mainly attributed to the presence of leading transfer membrane manufacturers in the region, availability of government and private financial support for life science research, and high target disease prevalence in the region.

Key Market Players

Thermo Fisher Scientific (US) held the second leadership position in the global market. Other prominent players in the global market included PerkinElmer (US), , Bio-Rad Laboratories (US), GE Healthcare (US), Pall Coporation (US), Advansta (US), GVS (OTCPK), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India),.

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=36975865